2021-05-12
Citrine Medicine Announces Strategic Partnership to bring Efmody® to China for Use in Adrenal Insufficiency (AI), including Congenital Adrenal Hyperplasia (CAH)
Media
-
-
2021-04-19Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China -
2021-03-16Citrine Medicine To Present at the 2021 WuXi Healthcare Forum and Participate in Two Additional Upcoming Healthcare Conferences -
2021-01-27Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH) -
2021-01-08Citrine Medicine to Participate at Three Upcoming Biotech Industry Conferences -
2020-10-28Chinese rare disease player inks first deal around narcolepsy drug Wakix after grabbing $80M to build an ecosystem -
2020-10-28Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix® (pitolisant) -
2020-07-13Citrine Medicine, a Rare Disease Platform Company Focused on the China Market, Launches After Raising $80 Million in Series A Funding